Emprumapimod

• Description :

  Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM) . Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain[1][2].

• CAS Number :

  [765914-60-1]

• Product Name Alternative :

  PF-07265803

• UNSPSC :

  12352005

• Target :

  P38 MAPK

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/emprumapimod.html

• Purity :

  99.12

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CC(C)CN1C2=CC(C(N[C@H](C(N)=O)CCN(C)C)=O)=C(OC3=C(C=C(C=C3)F)F)C=C2C=N1

• Molecular Formula :

  C24H29F2N5O3

• Molecular Weight :

  473.52

• References & Citations :

  [1]Dale Wright, et al. ARRY-797, a Potent and Selective Inhibitor of p38 Map Kinase, Inhibits LPS-Induced IL-6 and In Vivo Growth of RPMI-8226 Human Multiple Myeloma Cells.|[2]Antoine Muchir, et al. Abnormal p38α mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene mutation. Hum Mol Genet. 2012 Oct 1;21 (19) :4325-33.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• Isoform :

  P38α